PMID- 35287609
OWN - NLM
STAT- MEDLINE
DCOM- 20220317
LR  - 20220318
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Mar 14
TI  - Adverse effects of cell-free and concentrated ascites reinfusion therapy for 
      malignant ascites: a single-institute experience.
PG  - 268
LID - 10.1186/s12885-022-09298-6 [doi]
LID - 268
AB  - BACKGROUND: Cell-free and concentrated ascites reinfusion therapy (CART) is a 
      strategy for improving various intractable symptoms due to refractory ascites, 
      including hypoalbuminemia. CART has recently been applied in the treatment of 
      cancer patients. This study was performed to assess the safety of CART in a 
      single cancer institute. METHODS: We retrospectively reviewed 233 CART procedures 
      that were performed for 132 cancer patients in our institute. RESULTS: The median 
      weight of ascites before and after concentration was 4,720 g and 490 g (median 
      concentration rate, 10.0-fold), The median amounts of total protein and albumin 
      were 64.0 g and 32.6 g (median recovery rates, 44.9% and 49.0%), respectively. 
      Thirty-three adverse events (AEs) were observed in 22 (9.4%) of 233 procedures; 
      30 of these events occurred after reinfusion. The most common reinfusion-related 
      AEs were fever (13 events) and chills (10 events). Univariate analyses revealed 
      no significant relationships between the frequency of AEs and age, sex, 
      appearance of ascites, weight of harvested and concentrated ascites, the ascites 
      processing rate (filtration and concentration), weight of saline used for 
      membrane cleaning, amount of calculated total protein for infusion, or 
      prophylaxis against AEs; the reinfusion rate of >/= 125 mL/h or >/= 10.9 g/h of total 
      protein affected the frequency of AEs, regardless of the prophylactic use of 
      steroids. CONCLUSIONS: The observed AEs were mainly mild reactions after 
      reinfusion, which were related to a reinfusion rate of volume >/= 125 mL/h, a 
      simple indicator in practice, or total protein >/= 10.9 g/h. Although our study was 
      retrospective in nature and undertaken in a single institute, this information 
      may be helpful for the management of cancer patients with refractory malignant 
      ascites using CART.
CI  - (c) 2022. The Author(s).
FAU - Tsubokura, Misato
AU  - Tsubokura M
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Adegawa, Yuko
AU  - Adegawa Y
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Kojima, Minoru
AU  - Kojima M
AD  - Department of Hematopoietic Stem Cell Transplantation, National Cancer Center 
      Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Tanosaki, Ryuji
AU  - Tanosaki R
AD  - Department of Blood Transfusion and Cellular Therapy, National Cancer Center 
      Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Ohtake, Ryuzaburo
AU  - Ohtake R
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Kase, Yuki
AU  - Kase Y
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Iwashita, Nao
AU  - Iwashita N
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Kasane, Moemi
AU  - Kasane M
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Nakabayashi, Saori
AU  - Nakabayashi S
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Takeuchi, Sayaka
AU  - Takeuchi S
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Kato, Ken
AU  - Kato K
AD  - Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 
      5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Boku, Narikazu
AU  - Boku N
AD  - Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 
      5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Kanemitsu, Yukihide
AU  - Kanemitsu Y
AD  - Department of Colorectal Surgery, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Okusaka, Takuji
AU  - Okusaka T
AD  - Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center 
      Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Fujimoto, Hiroyuki
AU  - Fujimoto H
AD  - Department of Urology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, 
      Tokyo, 104-0045, Japan.
FAU - Yonemori, Kan
AU  - Yonemori K
AD  - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, 
      Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Ishiki, Hiroto
AU  - Ishiki H
AD  - Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Kawamura, Kimihiko
AU  - Kawamura K
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Satomi, Eriko
AU  - Satomi E
AD  - Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Matsushita, Hiromichi
AU  - Matsushita H
AUID- ORCID: 0000-0002-1629-6630
AD  - Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1, 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. hirommat@ncc.go.jp.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20220314
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Ascites/etiology/mortality/*therapy
MH  - Cell- and Tissue-Based Therapy/methods/*mortality
MH  - *Cell-Free System
MH  - Cross-Sectional Studies
MH  - Digestive System Neoplasms/*complications
MH  - Female
MH  - Humans
MH  - Infusions, Parenteral
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC8919605
OTO - NOTNLM
OT  - Adverse effects (AEs)
OT  - Cell-free and concentrated ascites reinfusion therapy (CART)
OT  - Fever
OT  - Malignant ascites
OT  - Reinfusion rate
COIS- The authors have no conflicts of interest to declare that are relevant to the 
      content of this article.
EDAT- 2022/03/16 06:00
MHDA- 2022/03/18 06:00
PMCR- 2022/03/14
CRDT- 2022/03/15 05:36
PHST- 2020/10/17 00:00 [received]
PHST- 2022/02/15 00:00 [accepted]
PHST- 2022/03/15 05:36 [entrez]
PHST- 2022/03/16 06:00 [pubmed]
PHST- 2022/03/18 06:00 [medline]
PHST- 2022/03/14 00:00 [pmc-release]
AID - 10.1186/s12885-022-09298-6 [pii]
AID - 9298 [pii]
AID - 10.1186/s12885-022-09298-6 [doi]
PST - epublish
SO  - BMC Cancer. 2022 Mar 14;22(1):268. doi: 10.1186/s12885-022-09298-6.